Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | YAP1 | P46937 | 1/20 | 0.45 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.45 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25181454 | 1.00 | TDP1 (0.46) | TDP1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2296124 | 1.00 | TDP1 (0.46) | TDP1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2294032 | 0.87 | MEN1 (0.46) | TDP1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL27711319 | 0.87 | MEN1 (0.46) | TDP1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2291932 | 0.87 | MEN1 (0.46) | TDP1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2296266 | 0.87 | KDM4E (0.42) | TDP1MEN1KMT2AALDH1A1HTT | |
| SCHEMBL2294819 | 0.87 | KDM4E (0.42) | TDP1MEN1KMT2AALDH1A1HTT | |
| SCHEMBL2293196 | 0.83 | CRHBP (0.55) | TDP1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2295641 | 0.83 | CRHBP (0.55) | TDP1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2295326 | 0.83 | ALOX5 (0.49) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156804-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-06-18 | — | — | US | claimed |
| EP-2809661-B1 | NOVEL MORPHOLINYL DERIVATIVES USEFUL AS MOGAT-2 INHIBITORS | LILLY CO ELI (US) | 2016-04-06 | — | — | EP | disclosed |
| EP-2809661-B1 | NOVEL MORPHOLINYL DERIVATIVES USEFUL AS MOGAT-2 INHIBITORS | LILLY CO ELI (US) | 2016-04-06 | — | — | EP | disclosed |
| US-8993568-B2 | Morpholinyl derivatives useful as MOGAT-2 inhibitors | ELI LILLY AND COMPANY (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993568-B2 | Morpholinyl derivatives useful as MOGAT-2 inhibitors | ELI LILLY AND COMPANY (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993568-B2 | Morpholinyl derivatives useful as MOGAT-2 inhibitors | ELI LILLY AND COMPANY (US) | 2015-03-31 | — | — | US | disclosed |
| US-20150005305-A1 | NOVEL MORPHOLINYL DERIVATIVES USEFUL AS MOGAT-2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2015-01-01 | — | — | US | disclosed |
| US-20150005305-A1 | NOVEL MORPHOLINYL DERIVATIVES USEFUL AS MOGAT-2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2015-01-01 | — | — | US | disclosed |
| US-20150005305-A1 | NOVEL MORPHOLINYL DERIVATIVES USEFUL AS MOGAT-2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2015-01-01 | — | — | US | disclosed |
| EP-2809661-A1 | NOVEL MORPHOLINYL DERIVATIVES USEFUL AS MOGAT-2 INHIBITORS | Eli Lilly and Company (US) | 2014-12-10 | — | — | EP | disclosed |
| CN-104080777-A | Morpholinyl derivatives as MOGAT-2 inhibitors | LILLY CO ELI | 2014-10-01 | — | — | CN | disclosed |
| WO-2013116075-A1 | BENZYL SULFONAMIDE DERIVATIVES USEFUL AS MOGAT - 2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2013-08-08 | — | — | WO | disclosed |
| WO-2013116065-A1 | NOVEL MORPHOLINYL DERIVATIVES USEFUL AS MOGAT-2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2013-08-08 | — | — | WO | disclosed |
| WO-2013116065-A1 | NOVEL MORPHOLINYL DERIVATIVES USEFUL AS MOGAT-2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2013-08-08 | — | — | WO | disclosed |
| US-20110257392-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | SANOFI-AVENTIS (FR) | 2011-10-20 | — | — | US | disclosed |
| US-20110251385-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | SANOFI-AVENTIS (FR) | 2011-10-13 | — | — | US | disclosed |
| US-7994315-B2 | Intermediate compound for synthesizing pharmaceutical agent and production method thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| EP-2221305-A1 | Method for synthesizing intermediate compound for synthesizing a pharmaceutical agent | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-08-25 | — | — | EP | disclosed |
| EP-2221304-A1 | Method for synthesizing intermediate compound for synthesizing a pharmaceutical agent | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-08-25 | — | — | EP | disclosed |
| US-20090156804-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257392-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MAPT, PSEN1, PSEN2 | TDP1 659/4885NPC1 1685/4885RAB9A 3397/4885 |
| US-20110251385-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MAPT, PSEN1, PSEN2 | TDP1 659/4885NPC1 1685/4885RAB9A 3397/4885 |
| US-20090156804-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MAPT, PSEN1, PSEN2 | TDP1 659/4885NPC1 1685/4885RAB9A 3397/4885 |
| US-20150005305-A1 | NOVEL MORPHOLINYL DERIVATIVES USEFUL AS MOGAT-2 INHIBITORS | MOGAT2, SOAT2, SOAT1 | TDP1 2511/4885NPC1 29/4885RAB9A 3424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.